Vor Biopharma Inc. (VOR) saw a 10% jump in stock price on Monday, closing at $2.42 per share. The increase comes after the addition of two CEOs, Alexander Cumbo and Michel Detheux, to the board, boosting investor confidence in the company’s leadership and strategic direction.

Cumbo, currently president and CEO of Solid Biosciences, brings over 30 years of commercial and executive leadership experience to Vor Biopharma. Detheux, president and CEO of iTeos Therapeutics, has successfully raised over $1 billion in capital and secured a $2 billion partnership with GSK.

Vor Biopharma Inc. (VOR) expressed enthusiasm over the addition of Cumbo and Detheux to its board as it advances telitacicept through late-stage development, aiming to provide transformative therapies to patients with autoimmune diseases. Investors are encouraged to explore other AI stocks for potentially higher returns and limited downside risk.

Read more at Yahoo Finance: Vor Biopharma (VOR) Jumps 10% on Addition of 2 CEOs to Board